Valeant Pharmaceuticals surprised the industry late last week when it upped its offer to acquire Allergan, the second such bid increase in a single week.
The Canadian company reportedly boosted its offer to $53 billion to acquire the Botox manufacturer. The offer stacks up at $72 a share, increased from last Wednesday’s offer of $58.30 a share.
In a statement from Valeant, the company said its increased offer is contingent upon Allergan responding promptly to the proposal so the two can launch negotiations.
Last month Allergan rejected a $46 billion offer from Valeant because it undervalued the company’s worth, Allergan said.
Full content: USA Today
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Germany and France Advocate for Major EU Competition Reform
May 29, 2024 by
CPI
Equifax Accused of Monopolizing Employment Verification Market in New Suit
May 29, 2024 by
CPI
Car Battery Makers to Challenge EU Cartel Charges in Brussels
May 29, 2024 by
CPI
Agri Stats Must Face Price-Fixing Lawsuit, Judge Rules
May 29, 2024 by
CPI
States Ramp Up Antitrust Efforts with Expanding Legal Teams
May 29, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI